ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products and clinical trial, registration, manufacturing, supply, ...
Net Revenue: $66.4 million for fiscal year 2025, a slight increase from $65.2 million in the prior year. ADHD Portfolio Revenue: $57.6 million, compared to $57.8 million in the prior year. Pediatric ...
Aytu BioPharma (NASDAQ:AYTU) is preparing to release its quarterly earnings on Tuesday, 2025-09-23. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
We expect erosion in sales from expired or expiring patents to result in a $100 billion headwind for the biopharma industry over the next five years. However, we think the headwind will be more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback